Endocrine Abstracts

Introduction: Graves’ orbitopathy and ocular myasthenia gravis are autoimmune disorders with overlapping clinical features that lead to difficulty in distinguishing both conditions. The simultaneous occurrence of both diseases is rare in frequency and occasionally followed by challenging management especially in pre-existing type 1 diabetes mellitus patient. We reported the case of ocular myasthenia gravis developed during the treatment in a patient with Graves‘ orbi...

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In a recent study, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 6 months compared to the standard treatment (intravenous glucocorticoids). Here we investigated the effects of sirolimus over a longer period of time.Methods: The study design entailed data anal...

Background: Teprotumumab showed significant improvements vs placebo for the treatment of thyroid eye disease (TED) in clinical trials1,2 and is approved in the United States (US) but currently not in the EU. Differences exist in baseline patient demographics and characteristics between EU and US patients. Here we examine outcomes in these 2 cohorts.Methods: Data from the EU and US sites for patients in the teprotumumab group (n =121) from the in...

Background: Graves orbitopathy (GO) is the most frequent and feared complication of Graves’ disease. In moderate-severe cases, intravenous (iv) glucocorticoids (GC) is the first-line treatment while Rituximab (RTX) is recommended as second-line treatment in patients non-responsive to GC. But data is scarce and contradictory.Objective: To investigate if patients with GO and poor response to iv GC benefit from a switch to RTX early in the treatment co...

Introduction: The initial clinical trials for teprotumumab excluded patients with previous orbital irradiation, surgery, glucocorticoid use (cumulative dose > 1gm), or biologic treatment. Therefore, information on the use of teprotumumab for patients who failed prior therapy is limited. Our purpose is to characterize the efficacy of teprotumumab for the treatment of recalcitrant TED.Methods: This is a multicenter retrospective study of all patients t...

Introduction: Knowing mental representations about the phenomenon of illness and medical care allows the clinical team to have better emotional handling of their patients, with gains in greater adherence to treatments. Graves’ Ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and orbit, being the most frequent extrathyroidal manifestation of Graves’ disease (GD). Many patients have psychological status changes even after su...

Objective: Appropriate administration of anti-inflammatory and immunosuppressive treatment (AIIST) is still important for patients with Graves’ orbitopathy (GO). This study aimed to clarify the incidence of and risk factors for GO treated with AIIST, among newly diagnosed Graves’ disease (GD) patients in Japan.Methods: A total of 1558 GD patients who were newly diagnosed at Ito Hospital during the year 2011 were investigated. AIIST included loc...

Objectives: Orbital radiotherapy (OR) is the most commonly used second-line treatment for the severe forms of Graves’ orbitopathy (GO). The aim of our study was to assess the changes in the therapeutic response, ocular manifestations of GO and quality of life (QoL) during the first year after OR.Methods: The study involved 26 consecutive patients with active moderate-to-severe GO indicated for OR, 18 females, mean age 57±12.5. At baseline all pat...

Introduction: Oxidative stress (OX) plays a role in the pathogenesis of moderate to severe Graves’ ophthalmopathy (AMS-GO).Aim: We evaluated the impact of clinical conditions related to OX on the outcome of parenteral glucocorticoids (PGLUC) therapy in AMS-GO.Methods: We retrospectively evaluated patients with AMS-GO treated with PGLUC from January 2013 to May 2022. GO clinical evaluation was performed at baseline, at 6 (W6), ...